Complement and HIV-I infection/HIV-associated neurocognitive disorders

Journal of NeuroVirology

Volumn 20, Issue 2, 2014, Pages 184-198

  Liu, Fengming ^a,b   Dai, Shen ^a,b   Gordon, Jennifer ^a   Qin, Xuebin ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHANDONG UNIVERSITY   (China)

Author keywords

CD59; Complement; Complement regulation; HAND; HIV 1; ILYd4

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; COMPLEMENT FACTOR H; DECAY ACCELERATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MANNOSE BINDING LECTIN; VIRUS ENVELOPE PROTEIN;

BLOOD LEVEL; BRAIN LEVEL; COGNITIVE DEFECT; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADAPTIVE IMMUNITY; AIDS DEMENTIA COMPLEX; ANTIBODIES, VIRAL; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, CD; COMPLEMENT SYSTEM PROTEINS; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; MANNOSE-BINDING LECTINS; VIRAL ENVELOPE PROTEINS;

EID: 84898823139     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-014-0243-9     Document Type: Review

References (137)

1. Aasa-Chapman MM, Hayman A, Newton P, Cornforth D, Williams I, Borrow P, Balfe P, McKnight A (2004) Development of the antibody response in acute HIV-1 infection. AIDS (London, England) 18:371-381
2. Aasa-Chapman MM, Holuigue S, Aubin K, Wong M, Jones NA, Cornforth D, Pellegrino P, Newton P, Williams I, Borrow P et al (2005) Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J Virol 79:2823-2830
3. Abe K, Miyazaki M, Koji T, Furusu A, Ozono Y, Harada T, Sakai H, Nakane PK, Kohno S (1998) Expression of decay accelerating factor mRNA and complement C3 mRNA in human diseased kidney. Kidney Int 54:120-130
4. Acosta J, Qin X, Halperin J (2004) Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr Pharm Des 10:203-211
5. Amet T, Ghabril M, Chalasani N, Byrd D, Hu N., Grantham A., Liu Z., Qin X., He JJ,Yu Q (2011). CD59 incorporation protects hepatitis C virus against complement-mediated destruction. Hepatology (Baltimore, Md.)
6. Bajtay Z, Speth C, Erdei A, Dierich MP (2004) Cutting edge: productive HIV-1 infection of dendritic cells via complement receptor type 3 (CR3, CD11b/CD18). J Immunol 173:4775-4778
7. Beck EJ, Santas XM, Delay PR (2008) Why and how to monitor the cost and evaluate the cost-effectiveness of HIV services in countries. AIDS (London, England) 22(Suppl 1):S75-S85
8. Belec L, Dupre T, Prazuck T, Tevi-Benissan C, Kanga JM, Pathey O, Lu XS, Pillot J (1995) Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection. J Infect Dis 172:691-697
9. Binley JM, Klasse PJ, Cao Y, Jones I, Markowitz M, Ho DD, Moore JP (1997) Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J Virol 71:2799-2809
10. Borrow P, Shattock RJ, Vyakarnam A, Group, E.W (2010) Innate immunity against HIV: a priority target for HIV prevention research. Retrovirology 7:84
11. Breitner S, Storkel S, Reichel W, Loos M (1995) Complement components C1q, C1r/C1s, and C1INH in rheumatoid arthritis. Correlation of in situ hybridization and northern blot results with function and protein concentration in synovium and primary cell cultures. Arthritis Rheum 38:492-498
12. Brodbeck WG, Mold C, Atkinson JP, Medof ME (2000) Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack. J Immunol 165:3999-4006
13. Bruder C, Hagleitner M, Darlington G, Mohsenipour I, Wurzner R, Hollmuller I, Stoiber H, Lass-Florl C, Dierich MP, Speth C (2004) HIV-1 induces complement factor C3 synthesis in astrocytes and neurons by modulation of promoter activity. Mol Immunol 40:949-961
14. Chatterjee A, Rathore A, Yamamoto N, Dhole TN (2011) Mannose-binding lectin (+54) exon-1 gene polymorphism influence human immunodeficiency virus-1 susceptibility in North Indians. Tissue Antigens 77:18-22
15. Chong YH, Lee MJ (2000) Expression of complement inhibitor protein CD59 in human neuronal and glial cell lines treated with HIV-1 gp41 peptides. J Neurovirol 6:51-60
16. Cohen MS, Hellmann N, Levy JA, DeCock K, Lange J (2008) The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Investig 118:1244-1254
17. Cooper NR, Jensen FC, Welsh RM Jr, Oldstone MB (1976) Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med 144:970-984
18. Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Bjorkqvist M, Petersen A, Jackson GS, Isaacs JD, Kristiansen M, Bates GP et al (2007) Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res 6:2833-2840
19. Datta PK, Rappaport J (2006) HIV and complement: hijacking an immune defense. Biomed Pharmacother 60:561-568
20. Davitz MA, Low MG, Nussenzweig V (1986) Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). J Exp Med 163:1150-1161
21. De Rosa SD, McElrath MJ (2008) T cell responses generated by HIV vaccines in clinical trials. Curr Opin HIV AIDS 3:375-379
22. Dierich MP, Stoiber H, Clivio A (1996) A "complementary" AIDS vaccine. Nat Med 2:153-155
23. Dzwonek A, Novelli V, Bajaj-Elliott M, Turner M, Clapson M, Klein N (2006) Mannose-binding lectin in susceptibility and progression of HIV-1 infection in children. Antivir Ther 11:499-505
24. Ebenbichler CF, Thielens NM, Vornhagen R, Marschang P, Arlaud GJ, Dierich MP (1991) Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 174:1417-1424
25. Eikelenboom P, Hack CE, Rozemuller JM, Stam FC (1989) Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch B Cell Pathol Mol Pathol 56:259-262
26. Ezekowitz RA, Kuhlman M, Groopman JE, Byrn RA (1989) A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus. J Exp Med 169:185-196
27. Fisicaro N1, Aminian A, Hinchliffe SJ, Morgan BP, Pearse MJ, D'Apice AJ, Cowan PJ (2000) The pig analogue of CD59 protects transgenic mouse hearts from injury by human complement. Transplantation 70(6):963-968
28. Gasque P, Fontaine M, Morgan BP (1995) Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J Immunol 154:4726-4733
29. Gauduin MC, Parren PW, Weir R, Barbas CF, Burton DR, Koup RA (1997) Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 3:1389-1393
30. Ge X, Wu L, Hu W, Fernandes S, Wang C, Li X, Brown JR, Qin X (2011) rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin Cancer Res 17:6702-6711
31. Gelman BB, Chen T, Lisinicchia JG, Soukup VM, Carmical JR, Starkey JM, Masliah E, Commins DL, Brandt D, Grant I et al (2012) The National NeuroAIDS Tissue Consortium brain gene array: two types of HIV-associated neurocognitive impairment. PLoS One 7:e46178
32. Giddings KS, Zhao J, Sims PJ, Tweten RK (2004) Human CD59 is a receptor for the cholesterol-dependent cytolysin intermedilysin. Nat Struct Mol Biol 11:1173-1178
33. Girard MP, Osmanov SK, Kieny MP (2006) A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 24:4062-4081
34. Gregersen JP, Mehdi S, Baur A, Hilfenhaus J (1990) Antibody- and complement-mediated lysis of HIV-infected cells and inhibition of viral replication. J Med Virol 30:287-293
35. Griffin GE, Leung K, Folks TM, Kunkel S, Nabel GJ (1991) Induction of NF-kappa B during monocyte differentiation is associated with activation of HIV-gene expression. Res Virol 142:233-238
36. Guo RF, Ward PA (2005) Role of C5a in inflammatory responses. Annu Rev Immunol 23:821-852
37. Haas PJ, van Strijp J (2007) Anaphylatoxins: their role in bacterial infection and inflammation. Immunol Res 37:161-175
38. Hart ML, Saifuddin M, Spear GT (2003) Glycosylation inhibitors and neuraminidase enhance human immunodeficiency virus type 1 binding and neutralization by mannose-binding lectin. J Gen Virol 84:353-360
39. Haurum JS, Thiel S, Jones IM, Fischer PB, Laursen SB, Jensenius JC (1993) Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. AIDS (London, England) 7:1307-1313
40. Holt DS, Botto M, Bygrave AE, Hanna SM, Walport MJ, Morgan BP (2001) Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood 98:442-449
41. Hu W, Ferris SP, Tweten RK, Wu G, Radaeva S, Gao B, Bronson RT, Halperin JA, Qin X (2008) Rapid conditional targeted ablation of cells expressing human CD59 in transgenic mice by intermedilysin. Nat Med 14:98-103
42. Hu W, Yu Q, Hu N, Byrd D, Amet T, Shikuma C, Shiramizu B, Halperin JA, Qin X (2010) A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS. J Immunol 184:359-368
43. Hu W, Ge X, You T, Xu T, Zhang J, Wu G, Peng Z, Chorev M, Aktas BH, Halperin JA et al (2011) Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res 71(6):2298-2307
44. Huber M, Trkola A (2007) Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 262:5-25
45. Huber M, Fischer M, Misselwitz B, Manrique A, Kuster H, Niederost B, Weber R, von Wyl V, Gunthard HF, Trkola A (2006) Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med 3:e441
46. Humbert M, Dietrich U (2006) The role of neutralizing antibodies in HIV infection. AIDS Rev 8:51-59
47. Israels J, Scherpbier HJ, Frakking FN, van de Wetering MD, Kremer LC, Kuijpers TW (2012) Mannose-binding lectin and the risk of HIV transmission and disease progression in children: a systematic review. Pediatr Infect Dis J 31:1272-1278
48. Jongen PJ, Doesburg WH, Ibrahim-Stappers JL, Lemmens WA, Hommes OR, Lamers KJ (2000) Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system. Acta Neurol Scand 101:116-121
49. June RA, Schade SZ, Bankowski MJ, Kuhns M, McNamara A, Lint TF, Landay AL, Spear GT (1991) Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation. AIDS (London, England) 5:269-274
50. Kacani L, Banki Z, Zwirner J, Schennach H, Bajtay Z, Erdei A, Stoiber H, Dierich MP (2001) C5a and C5a(desArg) enhance the susceptibility of monocyte-derived macrophages to HIV infection. J Immunol 166:3410-3415
51. Kim MK, Breitbach CJ, Moon A, Heo J, Lee YK, Cho M, Lee JW, Kim SG, Kang DH, Bell JC et al (2013) Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci Translat Med 5:185ra-163
52. Kutzler MA, Weiner DB (2008) DNA vaccines: ready for prime time? Nat Rev Genet 9:776-788
53. Letendre S (2011) Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antiviral Med 19:137-142
54. Letvin NL (2005) Progress toward an HIV vaccine. Annu Rev Med 56:213-223
55. Li H, Fu WP, Hong ZH (2013) Replication study in Chinese Han population and meta-analysis supports association between the MBL2 gene polymorphism and HIV-1 infection. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis 20:163-170
56. Lin RC, Herman J, Henry L, Daniels GL (1988) A family showing inheritance of the Inab phenotype. Transfusion 28:427-429
57. Lu S (2008) Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccin 4:449-452
58. Lund O, Hansen J, Soorensen AM, Mosekilde E, Nielsen JO, Hansen JE (1995) Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection. J Virol 69:2393-2400
59. Mangano A, Rocco C, Marino SM, Mecikovsky D, Genre F, Aulicino P, Bologna R, Sen L (2008) Detrimental effects of mannose-binding lectin (MBL2) promoter genotype XA/XA on HIV-1 vertical transmission and AIDS progression. J Infect Dis 198:694-700
60. Martinez-Pinna R, Madrigal-Matute J, Tarin C, Burillo E, Esteban-Salan M, Pastor-Vargas C, Lindholt JS, Lopez JA, Calvo E, de Ceniga MV et al (2013) Proteomic analysis of intraluminal thrombus highlights complement activation in human abdominal aortic aneurysms. Arteriosclerosis Thromb Vasc Biol 33:2013-2020
61. Mayer MM (1984) Complement. Historical perspectives and some current issues. Complement (Basel Switzerland) 1:2-26
62. Medof ME, Lublin DM, Holers VM, Ayers DJ, Getty RR, Leykam JF, Atkinson JP, Tykocinski ML (1987) Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci U S A 84:2007-2011
63. Montefiori DC, Cornell RJ, Zhou JY, Zhou JT, Hirsch VM, Johnson PR (1994) Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 205:82-92
64. Morgan BP (1999) Regulation of the complement membrane attack pathway. Crit Rev Immunol 19:173-198
65. Morgan BP, Gasque P (1997) Extrahepatic complement biosynthesis: where, when and why? Clin Exp Immunol 107:1-7
66. Morris L (2002) Neutralizing antibody responses to HIV-1 infection. IUBMB Life 53:197-199
67. Mosser DM, Brittingham A (1997) Leishmania, macrophages and complement: a tale of subversion and exploitation. Parasitology 115(Suppl):S9-S23
68. Nevo Y, Ben-Zeev B, Tabib A, Straussberg R, Anikster Y, Shorer Z, Fattal-Valevski A, Ta-Shma A, Aharoni S, Rabie M et al (2013) CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy. Blood 121:129-135
69. Nicholson-Weller A, Spicer DB, Austen KF (1985) Deficiency of the complement regulatory protein, "decay-accelerating factor," on membranes of granulocytes, monocytes, and platelets in paroxysmal nocturnal hemoglobinuria. N Engl J Med 312:1091-1097
70. Ozkaya Sahin G, Holmgren B, Sheik-Khalil E, da Silva Z, Nielsen J, Nowroozalizadeh S, Mansson F, Norrgren H, Aaby P, Fenyo EM et al (2013) Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent. J Virol 87:273-281
71. Pantophlet R, Burton DR (2006) GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24:739-769
72. Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, Taylor RP (2009) Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 183:749-758
73. Pellegrin I, Legrand E, Neau D, Bonot P, Masquelier B, Pellegrin JL, Ragnaud JM, Bernard N, Fleury HJ (1996) Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. J Acquir Immune Defic Syndr Hum Retrovirol 11:438-447
74. Pincus SH, Messer KG, Nara PL, Blattner WA, Colclough G, Reitz M (1994) Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers. J Clin Investig 93:2505-2513
75. Posner MR, Elboim HS, Cannon T, Cavacini L, Hideshima T (1992) Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis. AIDS Res Hum Retrovir 8:553-558
76. Pratt JR, Basheer SA, Sacks SH (2002) Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 8:582-587
77. Prohaszka Z, Hidvegi T, Ujhelyi E, Stoiber H, Dierich MP, Susal C, Fust G (1995) Interaction of complement and specific antibodies with the external glycoprotein 120 of HIV-1. Immunology 85:184-189
78. Prohaszka Z, Nemes J, Hidvegi T, Toth FD, Kerekes K, Erdei A, Szabo J, Ujhelyi E, Thielens N, Dierich MP et al (1997) Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection. AIDS (London, England) 11:949-958
79. Pruenster M, Wilflingseder D, Banki Z, Ammann CG, Muellauer B, Meyer M, Speth C, Dierich MP, Stoiber H (2005) C-type lectin-independent interaction of complement opsonized HIV with monocyte-derived dendritic cells. Eur J Immunol 35:2691-2698
80. Qin X, Gao B (2006) The complement system in liver diseases. Cell Mol Immunol 3:333-340
81. Qin X, Krumrei N, Grubissich L, Dobarro M, Aktas H, Perez G, Halperin JA (2003) Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic anemia with platelet activation and progressive male infertility. Immunity 18:217-227
82. Qin X, Hu W, Song W, Grubissich L, Hu X, Wu G, Ferris S, Dobarro M, Halperin JA (2009) Generation and phenotyping of mCd59a and mCd59b double-knockout mice. Am J Hematol 84:65-70
83. Reboul J, Schuller E, Pialoux G, Rey MA, Lebon P, Allinquant B, Brun-Vezinet F (1989) Immunoglobulins and complement components in 37 patients infected by HIV-1 virus: comparison of general (systemic) and intrathecal immunity. J Neurol Sci 89:243-252
84. Rees-Roberts D, Mullen LM, Gounaris K, Selkirk ME (2010) Inactivation of the complement anaphylatoxin C5a by secreted products of parasitic nematodes. Int J Parasitol 40:527-532
85. Reid ME, Mallinson G, Sim RB, Poole J, Pausch V, Merry AH, Liew YW, Tanner MJ (1991) Biochemical studies on red blood cells from a patient with the Inab phenotype (decay-accelerating factor deficiency). Blood 78:3291-3297
86. Reisinger EC, Vogetseder W, Berzow D, Kofler D, Bitterlich G, Lehr HA, Wachter H, Dierich MP (1990) Complement-mediated enhancement of HIV-1 infection of the monoblastoid cell line U937. AIDS (London, England) 4:961-965
87. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E et al (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209-2220
88. Richman DD, Wrin T, Little SJ, Petropoulos CJ (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100:4144-4149
89. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ (2009) The challenge of finding a cure for HIV infection. Science 323:1304-1307
90. Robinson HL (2007) HIV/AIDS vaccines: 2007. Clin Pharmacol Ther 82:686-693
91. Rozek W, Ricardo-Dukelow M, Holloway S, Gendelman HE, Wojna V, Melendez LM, Ciborowski P (2007) Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J Proteome Res 6:4189-4199
92. Rus H, Cudrici C, Niculescu F (2005) C5b-9 complement complex in autoimmune demyelination and multiple sclerosis: dual role in neuroinflammation and neuroprotection. Ann Med 37:97-104
93. Saifuddin M, Parker CJ, Peeples ME, Gorny MK, Zolla-Pazner S, Ghassemi M, Rooney IA, Atkinson JP, Spear GT (1995) Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CE59 in complement resistance of cell derived and primary isolates of HIV-1. J Exp Med 182:501-509
94. Saifuddin M, Hedayati T, Atkinson JP, Holguin MH, Parker CJ, Spear GT (1997) Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol 78:1907-1911
95. Saifuddin M, Hart ML, Gewurz H, Zhang Y, Spear GT (2000) Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1. J Gen Virol 81:949-955
96. Sanders ME, Koski CL, Robbins D, Shin ML, Frank MM, Joiner KA (1986) Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis. J Immunol 136:4456-4459
97. Sanders ME, Alexander EL, Koski CL, Frank MM, Joiner KA (1987) Detection of activated terminal complement (C5b-9) in cerebrospinal fluid from patients with central nervous system involvement of primary Sjogren's syndrome or systemic lupus erythematosus. J Immunol 138:2095-2099
98. Schmitz J, Zimmer JP, Kluxen B, Aries S, Bogel M, Gigli I, Schmitz H (1995) Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. J Clin Investig 96:1520-1526
99. Sheng A, Lan J, Wu H, Lu J, Wang Y, Chu Q, Jia Z, Song M, Liu L, Wang W (2010) A clinical case-control study on the association between mannose-binding lectin and susceptibility to HIV-1 infection among northern Han Chinese population. Int J Immunogenet 37:445-454
100. Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, Buckler-White A, Seaman M, Piatak M Jr, Lifson JD et al (2013) Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503:277-280
101. Singh KK, Lieser A, Ruan PK, Fenton T, Spector SA (2008) An age-dependent association of mannose-binding lectin-2 genetic variants on HIV-1-related disease in children. J Allergy Clin Immunol 122:173-180, 180 e171-172
102. Singh KK, Nathamu S, Adame A, Alire TU, Dumaop W, Gouaux B, Moore DJ, Masliah E, H.I.V.N.R.C.G. (2011) Expression of mannose binding lectin in HIV-1-infected brain: implications for HIV-related neuronal damage and neuroAIDS. Neurobehav HIV Med 3:41-52
103. Spear GT, Sullivan BL, Takefman DM, Landay AL, Lint TF (1991) Human immunodeficiency virus (HIV)-infected cells and free virus directly activate the classical complement pathway in rabbit, mouse and guinea-pig sera; activation results in virus neutralization by virolysis. Immunology 73:377-382
104. Spear GT, Takefman DM, Sullivan BL, Landay AL, Zolla-Pazner S (1993) Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol 67:53-59
105. Speth C, Stockl G, Mohsenipour I, Wurzner R, Stoiber H, Lass-Florl C, Dierich MP (2001) Human immunodeficiency virus type 1 induces expression of complement factors in human astrocytes. J Virol 75:2604-2615
106. Speth C, Dierich MP, Gasque P (2002a) Neuroinvasion by pathogens: a key role of the complement system. Mol Immunol 38:669-679
107. Speth C, Schabetsberger T, Mohsenipour I, Stockl G, Wurzner R, Stoiber H, Lass-Florl C, Dierich MP (2002b) Mechanism of human immunodeficiency virus-induced complement expression in astrocytes and neurons. J Virol 76:3179-3188
108. Speth C, Stoiber H, Dierich MP (2003) Complement in different stages of HIV infection and pathogenesis. Int Arch Allergy Immunol 130:247-257
109. Speth C, Williams K, Hagleitner M, Westmoreland S, Rambach G, Mohsenipour I, Schmitz J, Wurzner R, Lass-Florl C, Stoiber H et al (2004) Complement synthesis and activation in the brain of SIV-infected monkeys. J Neuroimmunol 151:45-54
110. Speth C, Dierich MP, Sopper S (2005) HIV-infection of the central nervous system: the tightrope walk of innate immunity. Mol Immunol 42:213-228
111. Spudich S, Gonzalez-Scarano F (2012) HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med 2:a007120
112. Stoiber H, Pinter C, Siccardi AG, Clivio A, Dierich MP (1996) Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp Med 183:307-310
113. Stoiber H, Clivio A, Dierich MP (1997) Role of complement in HIV infection. Annu Rev Immunol 15:649-674
114. Stoiber H, Kacani L, Speth C, Wurzner R, Dierich MP (2001) The supportive role of complement in HIV pathogenesis. Immunol Rev 180:168-176
115. Stoiber H, Speth C, Dierich MP (2003) Role of complement in the control of HIV dynamics and pathogenesis. Vaccine 21(Suppl 2):S77-S82
116. Stoiber H, Banki Z, Wilflingseder D, Dierich MP (2008a) Complement-HIV interactions during all steps of viral pathogenesis. Vaccine 26:3046-3054
117. Stoiber H, Soederholm A, Wilflingseder D, Gusenbauer S, Hildgartner A, Dierich MP (2008b) Complement and antibodies: a dangerous liaison in HIV infection? Vaccine 26(Suppl 8):I79-I85
118. Sugita Y, Tobe T, Oda E, Tomita M, Yasukawa K, Yamaji N, Takemoto T, Furuichi K, Takayama M, Yano S (1989) Molecular cloning and characterization of MACIF, an inhibitor of membrane channel formation of complement. J Biochem (Tokyo) 106:555-557
119. Sun X, Funk CD, Deng C, Sahu A, Lambris JD, Song WC (1999) Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc Natl Acad Sci U S A 96:628-633
120. Susal C, Kirschfink M, Kropelin M, Daniel V, Opelz G (1994) Complement activation by recombinant HIV-1 glycoprotein gp120. J Immunol 152:6028-6034
121. Szabo J, Prohaszka Z, Toth FD, Gyuris A, Segesdi J, Banhegyi D, Ujhelyi E, Minarovits J, Fust G (1999) Strong correlation between the complement-mediated antibody-dependent enhancement of HIV-1 infection and plasma viral load. AIDS (London, England) 13:1841-1849
122. Tan Y, Liu L, Luo P, Wang A, Jia T, Shen X, Wang M, Zhang S (2009) Association between mannose-binding lectin and HIV infection and progression in a Chinese population. Mol Immunol 47:632-638
123. Telen MJ, Green AM (1989) The Inab phenotype: characterization of the membrane protein and complement regulatory defect. Blood 74:437-441
124. Thieblemont N, Haeffner-Cavaillon N, Haeffner A, Cholley B, Weiss L, Kazatchkine MD (1995) Triggering of complement receptors CR1 (CD35) and CR3 (CD11b/CD18) induces nuclear translocation of NF-kappa B (p50/p65) in human monocytes and enhances viral replication in HIV-infected monocytic cells. J Immunol 155:4861-4867
125. Tweten RK (2005) Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. Infect Immun 73:6199-6209
126. Walker BD, Burton DR (2008) Toward an AIDS vaccine. Science 320:760-764
127. Welsh RM Jr, Cooper NR, Jensen FC, Oldstone MB (1975) Human serum lyses RNA tumour viruses. Nature 257:612-614
128. Welsh RM Jr, Jensen FC, Cooper NR, Oldstone MB (1976) Inactivation of lysis of oncornaviruses by human serum. Virology 74:432-440
129. Wu G, Hu W, Shahsafaei A, Song W, Dobarro M, Sukhova GK, Bronson RR, Shi GP, Rother RP, Halperin JA et al (2009) Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circulat Res 104:550-558
130. Wu G, Chen T, Shahsafaei A, Hu W, Bronson RT, Shi GP, Halperin JA, Aktas H, Qin X (2010) Complement regulator CD59 protects against angiotensin II-induced abdominal aortic aneurysms in mice. Circulation 121:1338-1346
131. Xu Y, Zhang C, Jia L, Wen C, Liu H, Wang Y, Sun Y, Huang L, Zhou Y, Song H (2009) A novel approach to inhibit HIV-1 infection and enhance lysis of HIV by a targeted activator of complement. Virol J 6:123
132. Yamashina M, Ueda E, Kinoshita T, Takami T, Ojima A, Ono H, Tanaka H, Kondo N, Orii T, Okada N et al (1990) Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 323:1184-1189
133. Ying H, Ji X, Hart ML, Gupta K, Saifuddin M, Zariffard MR, Spear GT (2004) Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization. AIDS Res Hum Retrovir 20:327-335
134. Yu Q, Yu R, Qin X (2010) The good and evil of complement activation in HIV-1 infection. Cell Mole Immunol 7:334-340
135. Zheng X, Saunders TL, Camper SA, Samuelson LC, Ginsburg D (1995) Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci U S A 92:12426-12430
136. Zhou X, Hu W, Qin X (2008) The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 13:954-966
137. Zhou HF, Yan H, Stover CM, Fernandez TM, Rodriguez de Cordoba S, Song WC, Wu X, Thompson RW, Schwaeble WJ, Atkinson JP et al (2012) Antibody directs properdin-dependent activation of the complement alternative pathway in a mouse model of abdominal aortic aneurysm. Proc Natl Acad Sci U S A 109:E415-E422